Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its stake in Catalyst Pharmaceuticals by 57.9%, owning approximately 0.63% of the company after acquiring 280,628 additional shares.
• Various institutional investors have recently modified their positions in Catalyst, with a significant portion of the stock (79.22%) now held by hedge funds and other institutional investors.
• Analysts currently rate Catalyst Pharmaceuticals with a consensus rating of "Buy", and it has a price target of $33.20.

Aberdeen Group plc boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 57.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 765,294 shares of the biopharmaceutical company's stock after buying an additional 280,628 shares during the quarter. Aberdeen Group plc owned 0.63% of Catalyst Pharmaceuticals worth $18,558,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Fox Run Management L.L.C. grew its holdings in Catalyst Pharmaceuticals by 50.4% during the first quarter. Fox Run Management L.L.C. now owns 57,118 shares of the biopharmaceutical company's stock worth $1,385,000 after acquiring an additional 19,136 shares during the period. E Fund Management Co. Ltd. acquired a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $237,000. Informed Momentum Co LLC lifted its holdings in Catalyst Pharmaceuticals by 3.4% in the first quarter. Informed Momentum Co LLC now owns 138,698 shares of the biopharmaceutical company's stock valued at $3,363,000 after acquiring an additional 4,574 shares during the period. HighTower Advisors LLC acquired a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $1,972,000. Finally, Knott David M Jr lifted its holdings in Catalyst Pharmaceuticals by 1.0% in the first quarter. Knott David M Jr now owns 212,000 shares of the biopharmaceutical company's stock valued at $5,141,000 after acquiring an additional 2,000 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total value of $42,272.00. Following the sale, the insider owned 41,081 shares of the company's stock, valued at $1,085,360.02. This trade represents a 3.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CPRX has been the subject of a number of recent analyst reports. Zacks Research cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Wall Street Zen downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $33.20.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX traded up $0.47 during midday trading on Friday, hitting $21.03. 637,527 shares of the stock were exchanged, compared to its average volume of 1,307,935. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.00 and a 52-week high of $26.58. The stock has a fifty day simple moving average of $21.34 and a 200 day simple moving average of $22.62. The firm has a market cap of $2.57 billion, a P/E ratio of 12.75, a P/E/G ratio of 0.83 and a beta of 0.70.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.